Table 1.

Characteristics of generated VST lines

VST line compound no. CMV specificity, SFC/1 × 105 IE1CMV specificity, SFC/1 × 105 pp65CD3, %CD4, %CD8, %CD56, %CD45RO+/CD62L+, %CD45RO+/CD62L, %HLA-AHLA-BHLA-DRHLA-DQNo. of patients screened*No. of patients treated
6790127118697.8174.2319.483.8875.4516.3302,3315,4407,1302,0643
679861280598.7917.7575.734.0540.344.8302,0240,5204,0803,0364
6802113135499.665.2092.821.6969.7527.5111,2335,5701,0703,0510
680882798699.7712.5983.183.1074.0920.1302,2440,5204,1303,0641
6814639257399.6828.2569.850.9941.5655.7802, 2408,1401, 0302,0511
682370071799.3910.9986.491.5147.5948.5911,6807,3503,0702,0231
683412872599.7715.4082.902.2764.6432.7202,2415,3504,0903,0361
6838205.521199.755.5787.468.7654.5036.4202,3013,3507,0802,0610
  • * Indicates how frequently the VST lines were determined to be the most suitable line for a screened patient.